|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
17 February 2020 |
|
Main ID: |
ChiCTR2000029878 |
|
Date of registration:
|
2020-02-16 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
The effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgery
|
|
Scientific title:
|
The effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgery |
|
Date of first enrolment:
|
2020-11-01 |
|
Target sample size:
|
Group 1:30;Group 2:30; |
|
Recruitment status: |
Pending |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=49258 |
|
Study type:
|
Interventional study |
|
Study design:
|
Parallel
|
|
Phase:
|
4
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Sheng Wang
|
|
Address:
|
1 Swan Road, Shushan District, Hefei, Anhui, China
|
|
Telephone:
|
+86 18935701573 |
|
Email:
|
18935701573@163.com |
|
Affiliation:
|
The South District of Anhui Provincial Hospital |
|
|
Name:
|
Jie Cheng
|
|
Address:
|
1 Swan Road, Shushan District, Hefei, Anhui, China
|
|
Telephone:
|
+86 13866730340 |
|
Email:
|
chengjie.hi@163.com |
|
Affiliation:
|
The South District of Anhui Provincial Hospital |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: ASA 2-3, age 18-65 years old, sinus rhythm, Hb>10g/dl, plan to have STA-MCA bypass surgery.
Exclusion criteria: Sinus bradycardia, uncontrolled hyperblood pressure, ie SBP>160mmHg, coronary artery disease, heart valve disease, hepatic or renal disfunction.
Age minimum:
18
Age maximum:
65
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
moyamoya disease
|
|
Intervention(s)
|
|
Group 1:iv norepinephrine;Group 2:iv phenylephrine;
|
|
Primary Outcome(s)
|
|
cerebral oxygennation;
|
|
Secondary Outcome(s)
|
|
urine output;LAC;tissue oxygen extraction;hepatic function;renal function;neurological complication;length of hospital stay;motality in 90days;
|
|
Source(s) of Monetary Support
|
|
selfunding
|
|
Ethics review
|
Status: Not approved
Approval date: 26/08/2013
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|